๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Quanzhou
Clinical trial register · China

Clinical Trials in Quanzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
BeiGene5 Second Xiangya Hospital of Central South University3 Fujian Cancer Hospital3 AstraZeneca2 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.2
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Quanzhou

41 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
A Multicenter, Randomized, Open-Label, Positive Controlled Phase III Study to Evaluate the Efficacy and Safety of VSA012 Injection in Participants With Paroxysmal Nocturnal Hemoglobinuria Who Are Naive to Complement Inhibitor Therapy
NCT07816237Paroxysmal Nocturnal Hemoglobinuria, PNH
Bisirna Therapeutics (Suzhou) Co., Ltd.
Phase 3
70
Beijing, Jilin City, Quanzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan
2026-10-29
Recruiting
Efficacy and Safety of Telitacicept in the Treatment of Refractory Rheumatoid Arthritis
NCT07796516Difficult-to-treat Rheumatoid Arthritis, Rheumatoid Arthritis
Peking University People's Hospital
Phase 2
420
Hefei, Beijing, Chongqing, Quanzhou, Guangzhou, Jiangmen, Shenzhen, Nanning
2026-09-01
Not yet open
Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer
NCT07469306Locally Advanced Rectal Cancer
Fujian Cancer Hospital
Phase 2
130
Fuzhou, Longyan, Quanzhou
2026-08-10
Not yet open
A Multicenter Exploratory Clinical Study of Iruplaltinib Combined With Pemetrexed as Neoadjuvant Therapy for Resectable ALK-Positive Non-Squamous Non-Small Cell Lung Cancer
NCT07771764ALK-positive Non Small Cell Lung Cancer
First Affiliated Hospital of Fujian Medical University
Phase 2
30
Fuzhou, Longyan, Quanzhou, Xiamen, Zhangzhou
2026-08-01
Not yet open
Kumorixilib Plus Capecitabine and Letrozole for Neoadjuvant Treatment of HR-Positive HER2-Negative Breast Cancer
NCT07691333HR+/HER2- Breast Cancer, Breast Neoplasms
Fujian Cancer Hospital
Phase 2
35
Fuzhou, Quanzhou
2026-06-30
Recruiting
Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis
NCT07516184Suspected Asthma
AstraZeneca
Not applicable
500
Beijing, Cangzhou, Changsha, Chengdu, Chongqing, Guangzhou, Kunming, Quanzhou
2026-06-10
Recruiting
Pre-Treatment DCE-MRI AI Models Predict Neoadjuvant Chemotherapy Response in HR+/HER2- Breast Cancer
NCT07702708HR+/HER2- Breast Cancer, Breast Neoplasms
Fujian Cancer Hospital
Observational
100
Fuzhou, Quanzhou, Ningde, Sanming
2026-06-01
Not yet open
Clinical Study of Universal CD19 CAR-ฮณฮดT Cell Injection in the Treatment of Adult Relapsed/Refractory B-cell Lymphoma
NCT07367685Recurrent/Refractory B-cell Lymphoma
The Second Affiliated Hospital of Fujian Medical University
Phase 1
6
Quanzhou
2026-05-01
Not yet open
Evaluation of Chiglitazar Sodium With Lifestyle Intervention for Reversing Prediabetes
NCT07558525Prediabetes
Second Xiangya Hospital of Central South University
Not applicable
472
Quanzhou, Guangzhou, Harbin, Luoyang, Wuhan, Changde, Changsha, Loudi
2026-04-18
Recruiting
FMT for the Prevention of Infectious Complications in Patients With Moderately Severe and Severe Acute Pancreatitis
NCT07464392Acute Pancreatitis
Changhai Hospital
Not applicable
150
Fuzhou, Quanzhou, Guangzhou, Qingyuan, Zhanjiang, Shanghai
2026-04-02
Active, closed
A Translational Study for Phenotyping and Endotyping Chinese Patients With NCFBE
NCT07245407Non-cystic Fibrosis Bronchiectasis
AstraZeneca
Observational
251
Beijing, Chongqing, Quanzhou, Lanzhou, Shenzhen, Zhanjiang, Nanning, Guiyang
2025-10-27
Recruiting
Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC
NCT07296705Muscle Invasive Bladder Cancer (MIBC)
Fujian Medical University Union Hospital
Phase 2
25
Fuzhou, Putian, Quanzhou, Sanming, Xiamen, Zhangzhou, Nanchang, Jinan
2025-10-25
Recruiting
A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
NCT07043725HER2-positive Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 3
544
Bengbu, Hefei, Wuhu, Beijing, Chongqing, Quanzhou, Xiamen, Zhangzhou
2025-09-15
Not yet open
Reinforcement Learned Automated Anesthesia Systems During Painless Abortion
NCT07132151Painless Abortion, Artificial Intelligence (AI), Ciprofol
Boston Intelligent Medical Research Center, Shenzhen United Scheme Technology Co., Ltd.
Not applicable
167
Fuzhou, Jinjiang, Quanzhou, Shenzhen, Zhengzhou, Chengdu, Chongqing
2025-09-08
Not yet open
A Study on Cardiopulmonary Exercise Tolerance Standards for Healthy Chinese Population
NCT07108296Oxygen Consumption, Cardiorespiratory Fitness
Affiliated Hospital of Changchun University of Chinese Medicine
Observational
4,620
Beijing, Quanzhou, Guangzhou, Nanning, Daqing, Harbin, Puyang, Zhengzhou
2025-09-01
Recruiting
Efficacy of Glycemic Improvement Project (GLITTER Study) in Type 1 Diabetes-GLITTER Study 2
NCT07097818Type 1 Diabetes
Second Xiangya Hospital of Central South University
Not applicable
400
Beijing, Quanzhou, Shenzhen, Tangshan, Luoyang, Wuhan, Changsha, Shenyang
2025-08-18
Active, closed
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
NCT07005128Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer
Amgen
Phase 3
350
Beijing, Quanzhou, Harbin, Jiamusi, Zhengzhou, Nanchang, Jinan, Shanghai
2025-08-18
Recruiting
Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma
NCT06829771Diffuse Large B Cell Lymphoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
90
Bengbu, Maโ€™anshan, Beijing, Fuzhou, Quanzhou, Lanzhou, Guangzhou, Liuzhou
2025-04-23
Recruiting
A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer
NCT07673029HER2-positive Breast Cancer
GeneQuantum Healthcare (Suzhou) Co., Ltd.
Phase 3
228
Bengbu, Fuyang, Hefei, Beijing, Chongqing, Fuzhou, Quanzhou, Guangzhou
2025-01-10
Not yet open
The Survey of Treatment and Metabolic Status of Type 1 Diabetes Mellitus (T1DM).
NCT06606509Type1 Diabetes Mellitus
Nanjing First Hospital, Nanjing Medical University
Observational
1,000
Anqing, Bengbu, Hefei, Wuhu, Beijing, Chongqing, Fuzhou, Quanzhou
2024-11-07
Active, closed
A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast Cancer
NCT06561607Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
542
Bengbu, Hefei, Beijing, Quanzhou, Zhangzhou, Lanzhou, Wuwei, Guangzhou
2024-10-11
Active, closed
Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)
NCT06456346Essential Thrombocythemia
Merck Sharp & Dohme LLC
Phase 3
300
Bengbu, Hefei, Beijing, Chongqing, Quanzhou, Xiamen, Guangzhou, Shijiazhuang
2024-07-16
Active, closed
Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab
NCT06211036Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer
Amgen
Phase 3
563
Beijing, Chongqing, Fuzhou, Quanzhou, Guangzhou, Guilin, Nanning, Cangzhou
2024-06-05
Recruiting
A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia
NCT06387069Acute Myeloid Leukemia
Hutchmed
Phase 3
316
Hefei, Beijing, Chongqing, Fuzhou, Quanzhou, Xiamen, Guangzhou, Guanzhou
2024-04-26
Recruiting
Protein Molecular Characteristics and Prognosis of Cervical Neuroendocrine Tumors
NCT06276309Neuroendocrine Neoplasm, China, Women, Cervical Cancer
Fujian Maternity and Child Health Hospital
Observational
300
Fuzhou, Ningde, Putian, Quanzhou, Zhangzhou, Wuhan, Changsha, Nanchang
2024-02-01
Active, closed
A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
NCT06079879Essential Thrombocythemia
Merck Sharp & Dohme LLC
Phase 3
340
Bengbu, Hefei, Beijing, Quanzhou, Xiamen, Guangzhou, Shijiazhuang, Zhengzhou
2023-12-31
Recruiting
Prospective Cohort of Patients With Intracerebral Hemorrhage
NCT06670456Stroke, Acute, Intracerebral Hemorrhage
De-zhi Kang
Observational
3,000
Fuzhou, Quanzhou, Xiamen, Zhangzhou, Liaocheng
2023-11-06
Recruiting
Effect of the Automatic Surveillance System on Surveillance Rate of Patients with Gastric Premalignant Lesions
NCT06039917Artificial Intelligence, Surveillance
Renmin Hospital of Wuhan University
Not applicable
1,460
Quanzhou, Wuhan, Shanghai
2023-09-10
Active, closed
Long-term Follow-up of Bivalent Human Papillomavirus (HPV) Vaccine Study in Women
NCT06776055Cervical Cancer, Vulvar Cancer, Vaginal Cancer, CIN - Cervical Intraepithelial Neoplasia
Shanghai Zerun Biotechnology Co.,Ltd
Observational
5,372
Lingchuan, Quanzhou, Xingโ€™an, Daming, Dingxing, Zhengding, Puyang, Wenquan
2023-03-27
Active, closed
A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer
NCT05609370Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer
BeiGene
Phase 1/2
113
Hefei, Beijing, Fuzhou, Quanzhou, Xiamen, Guangzhou, Shantou, Zhengzhou
2023-01-29
Active, closed
Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT05479994Leukemia, Lymphoma, Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma
BeiGene
Phase 2
100
Hefei, Beijing, Fuzhou, Quanzhou, Zhangzhou, Lanzhou, Guangzhou, Shaoguan
2022-10-25
Recruiting
OGT-assisted Overlap Esophagojejunostomy Versus Traditional Overlap Method
NCT05450835Gastric Cancer
Nanfang Hospital, Southern Medical University
Not applicable
344
Quanzhou, Guangzhou, Shantou, Ganzhou, Changsha, Hengyang, Changchun, Shenyang
2022-09-01
Recruiting
Multicenter Study of Fulminant Type 1 Diabetes in China
NCT05593081Diabetes Mellitus, Type 1
Second Xiangya Hospital of Central South University
Observational
240
Quanzhou, Guangzhou, Nanning, Zunyi, Haikou, Changsha, Yancheng, Nanchang
2022-05-20
Active, closed
Characteristics of Vaginal and Intestinal Microbiota and Cervical HPV Infection
NCT05003505Intestinal Microbiota, Vaginal Microbiota, HPV Infection
Fujian Maternity and Child Health Hospital
Observational
651
Fuzhou, Ningde, Quanzhou, Xiamen, Zhangzhou, Foshan, Shenzhen, Wuhan
2021-07-01
Active, closed
Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)
NCT04379635Non Small Cell Lung Cancer
BeiGene
Phase 3
453
Hefei, Beijing, Fuzhou, Quanzhou, Xiamen, Guangzhou, Jiangmen, Shantou
2020-05-29
Recruiting
Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma
NCT05713994Hepatocellular Carcinoma Non-resectable
Ze-yang Ding, MD
Observational
300
Quanzhou, Wuhan
2020-05-19
Active, closed
A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib
NCT04170283B-cell Malignancies
BeOne Medicines
Phase 3
955
Beijing, Fuzhou, Quanzhou, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanjing
2020-01-16
Active, closed
A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation
NCT04002297Mantle Cell Lymphoma; Non-Hodgkin Lymphoma
BeOne Medicines
Phase 3
510
Beijing, Fuzhou, Quanzhou, Guangzhou, Harbin, Zhengzhou, Wuhan, Changsha
2019-08-20
Active, closed
Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma
NCT03967977Urothelial Carcinoma
BeiGene
Phase 3
420
Hefei, Beijing, Chongqing, Fuzhou, Quanzhou, Xiamen, Guangzhou, Harbin
2019-05-29
Active, closed
A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL
NCT03336333Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
BeiGene
Phase 3
590
Hefei, Beijing, Chongqing, Fuzhou, Quanzhou, Guangzhou, Zhengzhou, Wuhan
2017-10-31
Active, closed
Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast Cancer
NCT02455141Breast Neoplasm
Shanghai Jiao Tong University School of Medicine
Phase 3
786
Fuding, Fuzhou, Quanzhou, Foshan, Guangzhou, Harbin, Jiangyin, Suzhou
2016-03
Rows per page Showing 1–41 of 41
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/quanzhou

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 41 of those studies with a site in Quanzhou.

How many clinical trials are recruiting in Quanzhou?

16 of the 41 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 9 have not yet opened recruitment, 16 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Quanzhou), 41 studies
PhaseStudiesRecruitingShare
Phase 315336.6%
Observational10524.4%
Not applicable7517.1%
Phase 26214.6%
Phase 1/2214.9%
Phase 1102.4%

Most active sponsors

Lead sponsors with the most studies (Quanzhou)
Lead sponsorStudiesRecruiting
BeiGene50
Fujian Cancer Hospital31
Second Xiangya Hospital of Central South University32
Amgen20
AstraZeneca21
BeOne Medicines20
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.21
Fujian Maternity and Child Health Hospital21
Merck Sharp & Dohme LLC20
Affiliated Hospital of Changchun University of Chinese Medicine10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.